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Results
During the two 4-year periods, all ischemic stroke survivors discharged on warfarin (n=12 790) were included in the study, irrespective of whether they had AF or not ( Figure I in the online-only Data Supplement). In the second period, a higher proportion of patients had AF, hypertension, and warfarin as single therapy (Table 1) . The proportion of patients with AF increased from 63.9% (n=3857) in the first period to 72.1% (n=4870) in the second period, with a mean increase of 9.3% per year (P<0.001). Mean time of follow-up was 2.6 years, with a minimum follow-up time of 1 year.
During 31 800 person-years, there were 1237 recurrent strokes, of which 127 were ICH. Annual rates of ICH ranged from 0.37% in the first period to 0.39% in the second period (adjusted hazard ratio, 1.04; 95% confidence interval, 0.73-1.48). The composite outcome of stroke and death decreased more in the second period than the first period, but it was not statistically significant ( Table 2) .
The sensitivity analyses, not considering the two 4-year intervals, supported the hypothesis that increased use of warfarin was not associated with an increase in subsequent ICH. Since 2001, the mean change per year in unadjusted risk of subsequent ICH was nonsignificant (hazard ratio, 0.98; 95% confidence interval, 0.91-1.06), with no alteration in the adjusted model.
Discussion
In this nationwide register-based study, the stroke recurrence rate was low. AF increased as an indication for warfarin, but the risk of warfarin-associated recurrent stroke, neither as ICH nor as ischemic event, did not change between 2001 and 2008.
In observational studies, the cumulative risk of stroke recurrence during the first year varies between 4.8% and 11.1%. 3, 4 These variations can be explained by methodological differences, such as the exclusion of early stroke recurrence (<28 days) in this study. The incidence of warfarin-associated ICH (≈0.4% in both periods) in our study reflected real life, but was lower than data presented for warfarin in trials of NOAC. 5, 6 In subgroups of patients with previous stroke, the annual rate of ICH in patients allocated warfarin is 0.8% in safety analyzes of dabigatran, 5 1.0% in analyzes of apixaban, 6 and 0.5% in analyzes of rivaroxaban. 7 AF, particularly in patients with previous stroke, is a major risk factor for stroke recurrence. 11 Even though AF, as an indication for warfarin, increased during the study period, the rate of recurrent ischemic stroke did not.
As the proportion of registered patients (>85%) and valid variables (>95%) in the Swedish Stroke Register is high, 9 we consider the results can be generalized to the Swedish population and other countries with an equally organized healthcare system. Despite potential limitations related to the register-based design, this study provides new information concerning ICH and stroke recurrence among ischemic stroke patients on warfarin. 
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